Dashboard
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of -18.75% and Operating profit at 9.76% over the last 5 years
- The company is Net-Debt Free
2
Negative results in Mar 26
3
Risky -
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 6,363 Million (Mid Cap)
NA (Loss Making)
NA
0.00%
569.30
-10,384.11%
1,430.72
Revenue and Profits:
Net Sales:
153 Million
(Quarterly Results - Jun 2026)
Net Profit:
-143 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.45%
0%
4.45%
6 Months
-11.34%
0%
-11.34%
1 Year
-16.25%
0%
-16.25%
2 Years
25.07%
0%
25.07%
3 Years
0.64%
0%
0.64%
4 Years
16.38%
0%
16.38%
5 Years
1.52%
0%
1.52%
Hainan Haiyao Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-18.75%
EBIT Growth (5y)
9.76%
EBIT to Interest (avg)
-2.38
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
6.37
Sales to Capital Employed (avg)
0.21
Tax Ratio
12.94%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0.66%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1082.63
EV to EBIT
-27.80
EV to EBITDA
-65.65
EV to Capital Employed
2.90
EV to Sales
9.27
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-10.42%
ROE (Latest)
-10384.11%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
153.10
168.20
-8.98%
Operating Profit (PBDIT) excl Other Income
-26.80
-9.10
-194.51%
Interest
44.30
39.50
12.15%
Exceptional Items
0.10
0.40
-75.00%
Consolidate Net Profit
-143.00
-81.60
-75.25%
Operating Profit Margin (Excl OI)
-557.90%
-402.10%
-15.58%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is -8.98% vs -12.17% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is -75.25% vs 57.83% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
825.30
971.50
-15.05%
Operating Profit (PBDIT) excl Other Income
-47.20
-460.20
89.74%
Interest
192.80
177.30
8.74%
Exceptional Items
0.10
-731.70
100.01%
Consolidate Net Profit
-456.20
-1,595.20
71.40%
Operating Profit Margin (Excl OI)
-301.60%
-664.60%
36.30%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -15.05% vs -33.33% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 71.40% vs -1,078.14% in Dec 2024
About Hainan Haiyao Co., Ltd. 
Hainan Haiyao Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






